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ABSTRACT
,QÀDPPDWRU\ERZHOGLVHDVH,%'ZLWKPDMRUPDQLIHVWDWLRQVDV&URKQ¶VGLVHDVH&'DQGXOFHUDWLYHFROLWLV
8& LVDFKURQLF LQWHVWLQDO LQÀDPPDWRU\GLVRUGHUZLWKDQXQNQRZQHWLRORJ\ZKLFKSDWKRJHQVLV LQYROYLQJ
PXOWLIDFWRULDOLPPXQHGLVRUGHUFKDUDFWHUL]HGE\FKURQLFUHODSVLQJLQÀDPPDWLRQRIWKHLQWHVWLQH0DQDJHPHQW
RI,%'GHSHQGVRQVWDJHDQGORFDWLRQRIWKHLQÀDPPDWLRQFRQVLVWRIWKHFODVVLFFRQYHQWLRQDOWUHDWPHQWDQG
the more new treatment with biologics agent. Biologics agent refers to monoclonal antibodies with activity 
GLUHFWHGDJDLQVWVSHFL¿FWDUJHWVLQYROYHGLQWKHSDWKRJHQHVLVRIFKURQLFLQÀDPPDWRU\FRQGLWLRQV$GYDQFHVLQ
WKHXQGHUVWDQGLQJRIWKHVSHFL¿FPHFKDQLVPVRISDWKRJHQHVLV,%'OHGWRWKHGHYHORSPHQWRIWDUJHWHGWUHDWPHQW
Today there are six biologics agent approved and used as therapy and there still many other biologics agent on 
UHVHDUFKSURJUHVV0DQ\UHSRUWVVKRZSRVLWLYHUHSRUWDERXWHI¿FDF\IRUWKHELRORJLFDOWKHUDS\FRPSDUHGZLWK
placebo and conventional treatment for the IBD. Limited by their cost and adverse effect that possibly happened, 
biologics agent is still promising therapy that change the course of IBD treatment.
Keywords: ,QÀDPPDWRU\ERZHOGLVHDVH,%'&URKQ¶VGLVHDVH&'XOFHUDWLYHFROLWLV 8&ELRORJLFDO
therapy, biologics agent.
ABSTRAK
3HQ\DNLWLQÀDPPDWRU\ERZHOGLVHDVH,%'WHUEDJLPHQMDGLSHQ\DNLW&URKQGDQNROLWLVXOVHUDWLIPHUXSDNDQ
SHUDGDQJDQ NURQLV LQÀDPDWRULN GHQJDQ HWLRORJL \DQJ EHOXP MHODV GLNHWDKXL GDQPHOLEDWNDQ JDQJJXDQ
LPXQLWDVPXOWLIDNWRULDO GLNDUDNWHULVWLNDQGHQJDQ LQÀDPDVLXVXV \DQJEHUXODQJ VHFDUDNURQLV7DWDODNVDQD
dari IBD bergantung kepada derajat penyakit dan lokasi lesi, tatalaksana terdiri dari terapi konvensional dan 
WHUDSLWHUEDUXGHQJDQDJHQELRORJLV$JHQELRORJLVPHUXSDNDQDQWLERGLPRQRNORQDO\DQJPHPLOLNLDNWL¿WDV
PHQJKDPEDWWDUJHWVSHVL¿NGDODPSURVHVLQÀDPDVLSDGD,%''HQJDQVHPDNLQEHUNHPEDQJQ\DSHPDKDPDQ
tentang mekanisme dari patogenesis IBD saat ini memicu perkembangan berbagai jenis agen biologis. Saat 
ini ada enam jenis agen biologis yang sudah disetujui dan digunakan sebagai terapi IBD dan banyak agen 
ELRORJLVODLQVHGDQJGDODPWDKDSSHQHOLWLDQ%HUEDJDLSHQHOLWLDQPHQXQMXNDQHIHNWL¿WDVWHUDSLELRORJLVDSDELOD
dibandingkan dengan plasebo dan terapi konvensional. Walaupun penggunaanya masih terbatas dikarenakan 
masalah biaya dan efek samping yang mungkin terjadi, agen biologis tetap merupakan terapi yang menjanjikan 
dan dapat merubah tatalaksana IBD.
Kata kunci: LQÀDPPDWRU\ERZHOGLVHDVH,%'SHQ\DNLW&URKQNROLWLVXOVHUDWLIWHUDSLELRORJLVDJHQELRORJLV
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INTRODUCTION
+HDOWKFDUHEXUGHQIRUPDQDJHPHQWRILQÀDPPDWRU\
bowel disease (IBD) is substantially high but has been 
evolved since the introduction of biologics agent in 
WKH EHJLQQLQJ RI WKH WZHQW\ ¿UVW FHQWXU\ VLQFH LWV
impact on reducing the need of surgeries and improved 
quality of life for IBD patient.1 Pathogensis on IBD 
involving multifactorial immune disorder characterized 
E\ FKURQLF UHODSVLQJ LQÀDPPDWLRQ RI WKH LQWHVWLQH
The two major manifestations of IBD were Crohn’s 
disease (CD) and ulcerative colitis (UC) which share 
similar symptoms including diarrhea, hematochezia, 
and abdominal pain, whereas the location and depth of 
LQÀDPPDWLRQDVZHOODVFRPSOLFDWLRQVDQGSUHYDOHQFH
can differ.2,3
Normally the immune system in gastrointestinal 
tract make a complex interaction between the innate, 
adaptive immune systems and intestinal microbes under 
homeostatic conditions. This homeostasis is disrupted 
ZLWK UHVXOW RI XQFRQWUROOHG LQWHVWLQDO LQÀDPPDWLRQ
in IBD. Therapy with most non-biological drug 
(aminosalicylates, steroids and immuno-modulators) 
provide symptomatic improvement but fail to stop the 
XQGHUO\LQJLQÀDPPDWRU\SURFHVVDQGGRQRWFKDQJHWKH
disease course. Biologics therapy for IBD have been 
revolutionized the treatment of patients with Crohn’s 
disease and have begun to have an impact on therapy 
for refractory ulcerative colitis. Biologics therapy 
proven to be highly effective.2-4
(3,'(0,2/2*< $1' 5,6. )$&725 2)
,1)/$00$725<%2:(/',6($6(
IBD can be diag nosed at any age from infancy to 
geriatrics population, with the majority of new cases 
are diagnosed in adolescence and early adulthood. 
In early twentieth century the incidence of IBD rose 
steadily in the western world but relatively rare in 
developing nations, but over the past few decades IBD 
also found emerged in newly industrialized countries 
such as in Asia, South America and Middle East and 
has evolved into a global disease with rising prevalence 
in every continent.5,6 
Over 1 million residents in the USA and 2.5 
million in Europe are estimated to have IBD, with 
substantial costs for health care. From ACCESS 
study, crude annual incidence of IBD per 100,000 
individuals were 1.37 in Asia. Incidence of IBD 
case in Indonesia was 0.88 per 100,000 individuals, 
with CD incidence was 0.33 and UC incidence was 
0.55.7 Epidemiological differences in IBD between 
the western world and newly industrial ized countries 
are primarily explained by genetic and environmental 
LQÀXHQFHVRQGLVHDVHGHYHORSPHQW Advances in health-
care infrastructure and methodological challenges 
in reporting epidemiological data also influence 
differences in reported incidence between countries 
and world regions. 7KH¿JXUHEHORZVXPPDUL]H WKH
KLVWRULFDORI,%'IURPWKH¿UVWLQWURGXFH1
)LJXUH7KHJOREDOSUHYDOHQFHRI,%'LQ
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,%'LVDFKURQLFLQWHVWLQDOLQÀDPPDWRU\GLVRUGHU
with an unknown etiology. IBD has been thought to be 
LGLRSDWKLFEXWLQÀXHQFHGE\JHQHWLFDQGHQYLURQPHQWDO
factors.2 It is believed to manifest in genetically 
predisposed individuals who has an abnormal immune 
response toward intestinal microbes after exposure 
to environmen tal triggers. Untill now 163 loci are 
known to confer susceptibility to Crohn’s disease 
and/or ulcerative colitis. Genes with the strongest 
associations are involved in the immune response to 
microbes, such as innate sensing of bacteria (NOD2), 
WKHLQÀDPPDWRU\UHVSRQVHWRPLFUREHV,/5DQG
autophagy (ATG16L1).1
Environmental exposures contribute to the etiology 
of IBD. Many of them have been studied, but none 
funda mentally can explain the truth pathogenesis 
of IBD. In the western world, smoking is the most 
consistently studied environmental deter minant of 
IBD. The hygiene hypothesis postulates that children in 
industrialized and high urbanization society have less 
exposure to microbes early in life, such that infections 
later will trigger an abnormal host immune response. 
Risk of IBD associated with antibiotic use in childhood, 
breast-feeding prove the role of the intestinal 
PLFURELRWDLQPRGXODWLQJLQÀDPDWLRQ'LHWDU\IDFWRUV
VXFKDVDORZ¿EUHGLHWDQGKLJKGLHWDU\IDWLQGLHWV
are associated with IBD, whereas consumption of tea 
was protective for IBD in Asia.1
3$7+2*(1(6,6$1' ,0081(0(&+$1,606 ,1
,1)/$00$725<%2:(/',6($6(,%'
Human intestine service as a immune system with 
complex interaction occured. Idiopathic intestinal 
LQÀDPPDWLRQVVXFKDV,%'RFFXUZKHQEDODQFHRIWKLV
immune system disrupted. Initially T-helper-1 (Th1) 
cells have been thought to play an important role in 
pathogenesis related to the chronicity of intestinal 
LQÀDPPDWLRQ HVSHFLDOO\ LQ&'ZKHUHDV7K FHOOV
have been thought to play an important role mainly 
in UC. Recently, additional factor like activation of 
Th17 cells and imbalance of Th17/T regulatory (Treg) 
cells are recognized to be an important component of 
IBD pathogenesis. Some other cells show to involved 
in the pathogenesis of IBD as can be viewed in this 
Figure below.2,3
)LJXUH+LVWRULFDOWLPHOLQHVRILQÀPPDWRU\ERZHOGLVHDVH,%'WKURXJKRXWWKHZRUOG1
)LJXUH3URLQÀDPPDWRU\LPPXQHFHOOVDQGWKHLUFURVVWDONLQSDWLHQWVZLWK,%'3
Treg FHO O   UHJXODWRU\ 7 FHO O   7*) W UDQVIRUPLQJ JURZWK IDFWRU   7H  W\SH  7 KHOSHU  FHO O   7H2:  type 2 
7 KHOSHU FHOO 7H W\SH  7 KHOSHU FHOO 7H W\SH  7 KHOSHU FHOO 1. FHOO QDWXUDO NLOOHU FHOO ,/ LQWHUOHXNLQ 
,)1LQWHUIHURQ71)WXPRUQHFURVLVIDFWRU
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(SLWKHOLDODQG&RPPHQVDO%DFWHULD
Epithelial surface of intestine acts as a barrier 
from harmful pathogens and place where commensal 
microorganisms live. The imbalance interaction 
between imune system with microbes develop chronic 
LQWHVWLQDO LQÀDPPDWLRQZKHQ FHUWDLQ HQYLURQPHQWDO
factors triggers the genetically susceptible hosts. The 
intestinal epithelial cell (IEC) layer make crypts and 
villi of intestine which contain different cells including 
enterocytes, goblet cells, neuroendocrine cells, Paneth 
cells, M cells, and epithelial resident intestinal stem 
cells. These layers composed a single columnar cell 
lining with a tight junction and the ability to secrete 
mucus that contain anti-microbial peptides. This 
IEC layer separate intra-luminal pathogens from the 
subepithelial lamina propria. The mucus layer covers 
the outer epithelial surface, with major constituent 
is glycosylated mucin produce from goblet cells and 
defensins from Paneth cells (A-defensin) and IECs 
(B-defensin). Reduced mucus production can be from 
dysfunction of paneth cell or depletion of goblet cell are 
¿QGLQJLQSDWLHQWZLWK,%'DQGLQFUHDVHGVXVFHSLELOLW\
WRGHYHORSLQÀDPDWLRQ2,3
Epithelial integrity depends on tight junctions 
function between IEC. Increase permeability of IEC 
layer make external pathogens are easily introduced, as 
happened on IBD. IEC also play a role as communicator 
between pathogens and lamina propria, normally small 
amounts of bacteria can translocate to submucosa to 
make antigen sampling and immune surveillance. High 
LQÀX[RILQWHVWLQDOFRQWHQWVDQGPLFURRUJDQLVPVRFFXU
when there is disruption of tight junction that thought to 
LQLWLDWHDQGPDLQWDLQDVXVWDLQHGLQÀDPPDWRU\UHVSRQVH
in IBD.2,3
Approximately 1011-1014 enteric commensal 
microorganisms from 300-500 bacterial species live in 
human intestine. The majority of commensal bacteria 
consist of gram-negative bacteria like Bacteroidetes 
and gram-positive bacteria like Firmicutes. Other 
minor bacteria such as Proteobacteria, Actinobacteria, 
Fusobacteria and Verrucomicrobia. Commensal 
bacteria play role in protecting intestinal homeostasis 
by affecting crucial nutrient provision, development 
of the immune system, and modulation of energy 
metabolism. There are some clues that commensal 
bacteria play an important role in the development of 
IBD. In IBD there is reduce of diversity and amount 
of commensal compared to that in healthy humans.2,3
,QQDWH DQG$GDSWLYH ,PPXQLW\ LQ ,QÀDPPDWRU\
%RZHO'LVHDVH,%'
The innate immune system serve as first line 
defensive against external pathogens. It provides 
rapid and non-specific protection from pattern 
recognition of pathogens. Human intestine innate 
immune system is composed of intestine epithelia, 
macrophages, monocytes, neutrophils, eosinophils, 
basophils, dendritic cells (DCs), and natural killer 
cells. Intraluminal pathogens communicate with innate 
immune cells through some receptors such as Toll like 
receptor (TLRs), nucleotide binding oligomerization 
domain leucine rich repeat receptors (NLRs), C-type 
lectin receptors (CLRs), and retinoic acid-inducible 
gene 1-like receptors (RLRs). Intestinal macrophages 
and DCs sense pathogen-associated molecular patterns 
(PAMPs) of microbes, activated signal pathways, 
VXFKDV1)N%SURGXFHSURLQÀDPPDWRU\F\WRNLQHV
chemokines, and anti-microbial peptides. This 
activation of macrophages by these process than lead 
to direct elimination of pathogens through release of 
free radicals and proteases. Further process results in 
antigen presentation to the adaptive immune system 
by DCs and macrophages, connecting the innate and 
adaptive immune system.2
Activated DCs present intraluminal pathogens to naive 
CD4+ T cells which pooled at secondary lymphoid organs 
of the intestine and modulate the polarization of naive 
CD4+ T cells to Treg cells and T helper cells, including 
Th1, Th2, and Th17 cells. In normal conditions, TLR 
signaling leads tolerance to luminal pathogens through 
down-regulation of pattern-recognition receptors and 
promotes mucosal wound healing. However in IBD, 
impaired TLR signaling leads to increased intestinal 
permeability and inappropriate mucosal healing.2 
The accumulation of both macrophages and DCs 
is observed in the lamina propria of IBD patients 
and in experimental colitis models. If interactions 
between DCs and T cells are interrupted, experimental 
T cell-mediated colitis is prevented. Impaired innate 
immune response might promote IBD development 
via inappropriate stimulation of adaptive immunity 
through failure to control microorganisms.2
Chronic inappropriate activation of the adaptive 
immune system against commensal microorganism has 
been thought to be the main pathogenesis of IBD. In 
Crohns disease patient there are increased production 
of IFN-g from Th1 cells and cytokines related with 
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Th17 cell, such as IL-17A/F, IL-21, IL-22, and CXCL8. 
While on UC patients there are increase production of 
Th2 cell-related cytokines, such as IL-5 and IL-13.2
0$1$*(0(17 2) ,1)/$00$725< %2:(/
DISEASE (IBD)
Management of IBD can be distinguished to two 
major groups, the classic conventional treatment 
and the more new treatment with biologics agent. 
The classical treatments consist of therapy with 
aminosalicylates, steroids and immuno-modulators 
drugs. These treatments differs for UC and CD and 
also differs for various stage of the disease. Treatment 
of UC is depend on the stage of the disease, patients 
with mild manifestations are usually treated with 
aminosalicylates, corticosteroids are given for those 
with moderate disease and cyclosporine is given 
to patients with severe disease. In CD therapy 
are depend on both location and behavior of the 
disease. The medication for crohns usually includes 
aminosalicylates and antibiotics to treat mild mucosal 
disease, corticosteroids to moderate disease, and 
ELRORJLFDOPROHFXOHVWRWUHDW¿VWXOL]LQJGLVHDVH2WKHU
therapy includes aminosalicylates, azathioprine, 
mercaptopurine, methotrexate, metronidazole can be 
used as maintenance therapies for both disease.6
Classically, immune-modulating treatments of IBD 
have focused on adaptive immunity. Corticosteroids 
KDYHEHHQZLGHO\XVHGWRWUHDWDFXWHÀDUHVRI,%'DQG
FOLQLFDO\ HIIHFWLYH 6XSSUHVVLRQRI SURLQÀDPPDWRU\
cytokines, such as TNF-a and IL-1b, is known to be 
the primary mechanism underlying how corticosteroids 
control IBD. Corticosteroids also play an important role 
in regulation of T helper cell differentiation and type I 
interferon (IFN) production. Other immunomodulators 
WR GRZQUHJXODWH WKH SURLQÀDPPDWRU\ F\WRNLQHV RI
T cells have been a well-established as treatment for 
IBD like cylosporine A, tacrolimus, methotrexate, 
azathioprine and 6-mercaptopurine. Non-specific 
immunosuppression using immunomodulators is 
generally safe and effective for disease control.6
Advances in the understanding of the specific 
mechanisms of IBD led to the development of targeted 
treatment, the biologics therapy. The biologic therapies 
as new therapy for IBD are still develop aim to reduce 
the side effects and to treat patients who do not respond 
satisfactorily to conventional therapies to improving 
the patient’s life quality.2,6
7+(%,2/2*,&$/7+(5$3<
The biological therapy refers to monoclonal 
antibodies with activity directed against specific 
targets involved in the pathogenesis of chronic 
LQÀDPPDWRU\ FRQGLWLRQV ,Q ,%'EDVHG RQ WKH VLWH
of action of biologics agent, it can be divide to two 
major class of drugs: biologics agent that modulate 
)LJXUH6XPPDU\RILQWHVWLQDOLPPXQHSURFHVV2
,/LQWHUOHXNLQ,)1LQWHUIHURQ71)WXPRUQHFURVLVIDFWRU7*)WUDQVIRUPLQJJURZWKIDFWRU7KKHOSHU7FHOO7UHJ
UHJXODWRU\7FHOO7&57FHOOUHFHSWRU1)N%QXFOHDUIDFWRUNDSSDOLJKWFKDLQHQKDQFHURIDFWLYDWHG%FHOO7/5
WROOOLNHUHFHSWRU12'QXFOHRWLGHROLJRPHUL]DWLRQGRPDLQ
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DQWLLQÀDPPDWRU\ F\WRNLQHV LQFOXGLQJ DJHQWV WKDW
WDUJHWRUDQWLWXPRUQHFURVLVIDFWRU71)LQÀL[LPDE
adalimumab, certolizumab, golimumab), agents 
that target interleukin (IL)-12/23 (ustekinumab) 
and agents that target integrins/anti-cell adhesion 
molecule (natalizumab, vedolizumab). To understand 
the mechanism of biologics agent, we need to look 
back on the pathogenesis of the IBD and potential of 
therapy that can be applicable. Dozens of novel agents 
based on recent advances in the understanding of the 
mucosal immune system for IBD pathogenesis have 
been developed. 2
%LRORJLFV$JHQWWKDW0RGXODWH$QWLLQÀDPPDWRU\
&\WRNLQHV
The era of biologic therapy began with an anti-TNF 
DJHQW LQÀL[LPDE IRU SDWLHQWVZLWK&'71)Į KDV
been thought to play an important role in patogenesis 
RI ,%'71)Į LV D SURLQÀDPPDWRU\ F\WRNLQH WKDW
produced by activated macrophages, monocytes, and 
T lymphocytes. Human intestine has two forms of 
71)ĮWKHWUDQVPHPEUDQH71)P71)DQGVROXEOH
TNF (sTNF). mTNF is expressed on the surface of 
CD14+ macrophages and targets TNF-R2 of T cells, 
and sTNF is secreted by several immune cells as a 
signaling molecule and targets TNF-R1 of effector 
cells. In IBD, increased levels of both mTNF and sTNF 
VXSSRUWWKHSURLQÀDPPDWRU\HIIHFWRILQÀDPHGJXW
such as angiogenesis, Paneth cell death, production 
RIPDWUL[PHWDOORSURWHLQDVHIURPP\R¿EUREODVWVDQG
the undermining of the barrier function of IECs.2,3 
6HYHUDODQWL71)ĮPRQRFORQDODQWLERGLHVKDYHEHHQ
developed and showed effectiveness for induction 
and maintenance of remission, as well as mucosal 
healing of IBD. These antibodies may activate various 
mechanisms involved in the immune response, such 
as induction of apoptosis as well as the blockage of 
growth factors for theTh cells, antibody production, 
and complement activation. However, another anti-
71) DJHQW WKDW WDUJHWV V71) VKRZHG QR EHQH¿WV
regarding treatment of IBD.2,6
Other important cytokines involved in the 
pathogenesis of IBD are related to Th17 cells (IL-17A, 
7DEOH,QÀDPPDWRU\ERZHOGLVHDVH,%'WUHDWPHQWVDQGWKHLUFKDUDFWHULVWLF6
Treatment 5HODWHGGUXJV 0HFKDQLVPRIDFWLRQ Features
Aminosalicylates Mesalamine
Olsasalazine
Balsalazide
Sulfasalazine
,QKLELWLRQRI,/71)ĮDQG3$)GHFUHDVHG
antibody secretion
/RFDOO\LPPXQRVXSUHVVLYHQRQVSHFL¿F
inhibition of cytokines.
Medium cost
Immunomodulators Azathioprin
6-mercaptopurin
Methotrexate
Blockage of de novo pathway of purine 
synthesis.
Antiproliferative
effects, reduction of
LQÀDPPDWLRQ
Corticosteroids Budesonide
Hydrocortisone
Methylprednisolone
Prednisone
Blockage of phospholipase A2 in the 
arachidonic acid cascade altering the 
balance between prostaglandins and 
OHXNRWULHQHV
Stimulation of apoptosis of lamina propria 
O\PSKRF\WHV
Suppression of the transcription of cytokines.
High
immunosuppression,
Risk of potential
infections,
Adverse
effects with long
periods of use,
Low cost.
Biologicals: 
Anticytokine drugs
,QÀL[LPDE
Adalimumab
Certolizumabpegol
Golimumab
Ustekinumab
Induction of apoptosis in
3URLQÀDPPDWRU\FHOOV
%LQGLQJVSHFL¿FDOO\WR71)D,
Blockage of the interaction the receptor.
6SHFL¿FLQKLELWLRQRI
cytokine,
Immunosuppression,
high cost,
Advanced technology required.
Biologicals: 
anti-cell adhesion 
molecule
Vedolizumab
Natalizumab
Inhibition of migration. 6SHFL¿FLQKLELWLRQRIFHOODGKHVLRQPROHFXOHV
High cost,
Advanced technology required.
,/LQWHUOHXNLQ3$)SODWHOHWDFWLYDWLQJIDFWRU71)WXPRUQHFURVLVIDFWRU
)LJXUH  %LRORJLFV DJHQW DQG WDUJHW DFWLRQ UHODWHG WR
LQÀDPPDWRU\ SURFHVV EODFN VKRZHG EHQH¿WV YLROHW QR
EHQH¿WV2 
$3&DQWLJHQSUHVHQWLQJFHOO,(&LQWHVWLQDOHSLWKHOLDOFHOO71)WXPRUQHFURVLV
IDFWRU0+&PDMRUKLVWRFRPSDWLELOLW\FRPSOH[7&57FHOO UHFHSWRU-$.
-DQXV NLQDVH7*) WUDQVIRUPLQJJURZWK IDFWRU ,/ LQWHUOHXNLQ0$G&$0
mucosal vascular addressing cell adhesion molecule
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IL21, IL-22, and IL-23). Th17 cells are differentiated 
from naïve CD4+ T cells that are stimulated with 
transforming growth factor (TGF). The inflamed 
intestinal tissue of IBD patients was shown to contain 
higher levels of Th17 cells and its cytokines. Exact role 
of Th17 cells and their cytokines in regards to intestinal 
LQÀDPPDWLRQKDVQRW\HWEHHQIXOO\XQGHUVWRRG%DVHG
on those mechanism, recently new drugs have been 
HPHUJHG VXFKDV ,)1ȖDQWLERG\ IRQWROL]XPDE DQWL
IL-17A secukinumab.2,3 Therapy such as Ustekinumab, 
ABT-874, and apilimod mesylate designed to targeting 
PXOWLSOH F\WRNLQHV LQ LQÀDPDWRU\ SURFHVV DQG LW LV
thought to be a reasonable approach in the treatment 
of IBD since complex interactions between various 
cytokines happened in its pathogenesis.2
Biologics Agent that Targeting Inter-/intra-cellular 
6LJQDOLQJ3DWKZD\V
Proinflammatory cytokines promote activation 
of intracellular signal transduction and end result is 
SURGXFWLRQ RI LQÀDPPDWRU\ SURWHLQV -DQXV NLQDVH
(JAK) and Signaling transducers and activator of 
transcription (STAT) cytokine signaling pathways are 
recently thought to be a potential therapeutic target 
RI ,%'9DULRXVNH\F\WRNLQHVVXFKDV ,)1Ȗ ,/
IL-4, IL-7, IL-9, IL-15, IL-12, IL-21, IL-22, and 
IL-23 depend on the JAK-signaling pathway. JAK 
inhibition might result in downregulation of multiple 
LQÀDPPDWRU\ F\WRNLQHV7KH -$. IDPLO\ FRQVLVWV
of four intracellular proteins, JAK1, JAK2, JAK3, 
and tyrosine kinase (TYK) 2. Some drugs develop 
to Targeting inter-/intra-cellular signaling pathways 
prove to be effective such as JAK 1/3 tofacitinib, 
oral SMAD7 anti-sense oligonucleotide-mongersen. 
2WKHUGUXJVVKRZHGQRFOLQLFDOEHQH¿WRQ,%'VXFK
as visilizumab and abatacept. 2
%LRORJLFV DJHQW WKDW LQKLELW WKH O\PSKRF\WH
WUDI¿FNLQJ
Pathogenesis of IBD involving the role of 
lymphocytes and this cell must travel from their pool to 
WKHLQWHVWLQH/\PSKRF\WHVH[SUHVVVSHFL¿FFHOOVXUIDFH
DGKHVLRQPROHFXOHVWDUJHWLQJVSHFL¿FRUJDQVWRIDFLOLWDWH
the travel process. From this concept, selective agent 
to inhibition of those adhesion molecules potentially 
change the development of IBD. Those drugs such 
DV QDWDOL]XPDE PRQRFORQDO DQWLERG\ DJDLQVW Į
integrin), vedolizumab (monoclonal antibody against 
Į LQWHJULQ HWUROL]XPDE PRQRFORQDO DQWLERG\
against the ß7 subunit of integrin) and PF-00547659 
(monoclonal antibody against MAdCAM-1). 2
1HZELRORJLFVDJHQW
A variety of new biologics specific to IBD 
pathogenesis are now emerging and under clinical 
investigation. The basic mechanism targeting different 
process from pathogenesis that involved, these can be 
VHHQRQ¿JXUHEHORZ3
)LJXUH7KH7FHOOF\WRNLQHWUHHLQ,%'DQGSRWHQWLDOELRORJLFWUHDWPHQW3
7*)WUDQVIRUPLQJJURZWKIDFWRU7+W\SH7KHOSHUFHOO7+W\SH7KHOSHUFHOO7+W\SH7KHOSHUFHOO7+
W\SH7KHOSHUFHOO7+W\SH7KHOSHUFHOO7UHJUHJXODWRU\7FHOO
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Tissue remodelling and destruction in patients with 
IBD is controlled by matrix metalloproteinas (MMPs). 
In IBD expression of MMP9 was found to be increased, 
particularly in patients with UC. Experimental models 
RI LQÀDPPDWLRQKDYHVXJJHVWHGDQ LPSRUWDQW UROHRI
MMP9 in impairing colonic epi thelial permeability and 
DXJPHQWLQJLQÀDPPDWLRQYLDDFWLYDWLRQRIP\RVLQOLJKW
chain kinase (MLCK). MMP9 favoured angiogenesis 
DQGFUHDWHGDSURWHRO\WLFHQYLURQPHQWLQWKHLQÀDPHG
gut of a mouse model of colitis that stimulated the 
LQÀX[ RIP\HORLG FHOOV LQWR WKH FRORQLF HSLWKHOLXP
and the production of TNF. Currently a potent and 
highly selective allosteric MMP9 inhibitor (humanized 
monoclonal antibody GS-5745) has been developed 
and is currently being tested in clinical trials in patients 
ZLWK,%'EXWLQVXI¿FLHQWHYLGHQFHRIWUHDWPHQWEHQH¿W3
$QRWKHUGUXJVWDUJHWWRDPHOLRUDWHWLVVXH¿EURVLV
in IBD through enzymes con trolling degradation of 
matrix compounds. Carbohydrate sulfotransferase 
 &+67 LV D VSHFL¿F HQ]\PHELRV\QWKHVL]LQJ
chondroitin sulfate E that binds to various pathogenic 
PHGLDWRUVDQGIDYRXUVWLVVXH¿EURVLV&+67UHGXFHG
colitis activity and intestinal accumu lation of F4/80+ 
PDFURSKDJHV DQG(575¿EUREODVWV 6710
a synthetic double-stranded RNA oligonucleotide 
directed against CHST15 showed a reduction of 
HQGRVFRSLF LQÀDPPDWLRQDVFRPSDUHGZLWKSODFHER
therapy and also histological analyses revealed that 
6710UHGXFHVWLVVXH¿EURVLVLQ&URKQ¶VGLVHDVH3
&855(17%,2/2*,&6$*(1786('
The current use of biologic therapy is limited 
by their cost. With the expiration of patents for 
certain biologics, and the development of biosimilars 
(biological products that are highly similar to the 
reference product but can be produced at a lower 
FRVWZLWKVLPLODUHI¿FDF\ZLOOFKDQJHWKHFRXUVHRI
IBD treatment. Anti-tumor necrosis factor (anti-TNF) 
DJHQWV DUH WKH ¿UVW DQG FXUUHQWO\ WKHPRVWZLGHO\
used biologic agents.8 Several parameters should 
EH FRQVLGHUHGZKHQ FKRRVLQJ D ¿UVWOLQH ELRORJLF
DJHQW LQFOXGLQJ WKH HI¿FDF\ VDIHW\SUR¿OH URXWHRI
)LJXUH1HZWKHUDSHXWLFDSSURDFKHVLQ,%'ZLWKWKHLUVSHFL¿FWDUJHWV3
,(&LQWHVWLQDOHSLWKHOLDOFHOO,/5,/UHFHSWRU0$G&$0PXFRVDODGGUHVVLQFHOODGKHVLRQPROHFXODU003PDWUL[
PHWDOORSURWHLQDVH5255$5UHODWHGRUSKDQUHFHSWRU7UHJ cell: regulatory T cell.
)LJXUH$SURSRVHGDOJRULWKPIRUFOLQLFDOSUDFWLFHRI%LRORJLF
agents in IBD.10 
)RUSHULDQDO¿VWXODV WKH OHYHORIHYLGHQFH LVZHDN IRUYHGROL]XPDE71)
tumor necrosis factor.
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administration, patient preference and cost. A proposed 
algorithm for using biologic agents in IBD can be seen 
LQ¿JXUHEHORZ10 
Patients with Crohn’s disease who are refractory 
to standard medications, infliximab or adalimumab 
could be initiated. Vedolizumab has been approved for 
induction and maintenance therapy for Crohn’s disease 
and ulcerative colitis. The use of natalizumab and 
certolizumab pegol is still restricted to a few countries due 
WRDQXQFOHDUEHWZHHQULVNDQGEHQH¿WLQ,%'WUHDWPHQW10
Response for the treatment can be adequate 
response or non-response. In patient with adequate 
SULPDU\UHVSRQVHWRD¿UVWOLQHDQWL71)WKHUDS\QR
switch between anti-TNF agents should be proposed, 
as switching is associated with loss of tolerance and 
HI¿FDF\1RQUHVSRQVLYHSDWLHQWFDQEHIRXQGXSWR
30% of total case. Non-response case divide into two 
type the primary non-response and secondary loss of 
response. If there is no response to initial treatment 
with anti-TNF it is called as primary non-responders. 
These type patient will unlikely to respond to another 
anti-TNF agent and require to switch to another class 
of biologic agent, such as vedolizumab. Secondary 
non-responders are patients who have a transient 
response but later will experience a loss of response to 
anti-TNF therapy. If this happened, the measurement 
of drug levels and anti-drug antibodies may help guide 
the next decision. Patients with subtherapeutic drug 
OHYHOV UHTXLUH GRVH LQWHQVL¿FDWLRQZKLOH SDWLHQWV
with detectable antibodies against one anti-TNF may 
EHQH¿W IURP VZLWFKLQJ WR DQRWKHU DQWL71) DJHQW
Secondary non-responders with adequate drug levels 
should switch to a different class of biologic agent.9,10
3RVLWLRQRIQHZELRORJLFVDJHQWLQWKHWUHDWPHQW
RI,QÀDPPDWRU\%RZHO'LVHDVH,%'
New target molecules for biologics agent and 
cellular therapy have been develop and this may provide 
alternative therapy. As for many other biologics agent 
untill now still on research progress. Because of no data 
in long-term safety for ustekinumab, tofacitinib, and 
mongersen, the use of these medications in patients at 
high risk of infection is not recommended recently.10
()),&$&<2)%,2/2*,&$/7+(5$3<
There are a lot of study about the using of biological 
therapy on IBD that has been published. Curently six 
biologic agents are approved for the treatment of IBD: 
LQÀL[LPDE DGDOLPXPDE JROLPXPDE FHUWROL]XPDE
pegol, natalizumab and vedolizumab. Several meta-
analyses have been conducted in both Crohn’s disease 
DQGXOFHUDWLYHFROLWLV WRFRPSDUH WKHHI¿FDF\RI WKH
various biologic agents. Most of the results show 
positive report for biological treatment compared with 
placebo for the treatment of IBD. Some study also 
compares one biological treatment to another drugs to 
show which one more effective for inducing remission 
or maintanance therapy.12,13
0HWDDQDO\VLVIURPYLFNHUVHWDODVVHVHI¿FDF\RI
Biologics agent used in ulcerative colitis showed that 
all biologics were superior than placebo in induction 
of clinical response, remission and mucosal healing 
)LJXUH,QLQGXFWLRQRIUHPLVVLRQLQÀL[LPDEVKRZ
VLJQL¿FDQWLPSURYHPHQWRYHUDGDOLPXPDELQFOLQLFDO
response, clinical remission and mucosal healing. 
:LWK QR RWKHU VLJQL¿FDQW GLIIHUHQFH EHWZHHQ RWKHU
biologics exist. In maintenance study vedolizumab 
show significantly difference in durable clinical 
response and rates of mucosal healing compared with 
other biologics agent (Table 4).12
 Meta-analysis from Hazlewood et al showed that 
LQÀL[LPDELQFOXGLQJFRPELQDWLRQRILQÀL[LPDEZLWK
azathioprine, adalimumab and vedolizumab were 
superior from placebo for induction and maintaining 
of remission on CD. This result also showed that the 
most effective agents for induction and maintaining 
7DEOH&KDUDFWHULVWLFVDQGGRVDJHRIELRORJLFDOWUHDWPHQWVIRU,%'4
Drug
7\SHRI
monoclonal 
DQWLERG\
Target +DOIOLIHGD\V Route
,QGXFWLRQSKDVH Maintenance phase
Dosage Interval Dosage Interval
,QÀL[LPDE Chimeric IgG1 71)Į 7.7-9.5 IV 5mg/kg W0-W2-W6 5 mg/kg Every 8 weeks
Adalimumab Human IgG1 71)Į 10-20 SC 160 mg W0 40 mg Every 2 weeks
80 mg W2
Certozulimab 
pegol
Humanized 
pegylated Fab IgG4
71)Į 14 SC 400 mg W0-W2-W4 400 mg Every 4 weeks
Golimumab Human IgG1 71)Į 8-16 SC 200 mg W0 50-100 mg Every 4 weeks
100 mg W2
CPT-13 Chimeric IgG1 71)Į 7.7-9.5 IV 5mg/kg W0-W2-W6 5 mg/kg Every 8 weeks
Natalizumab Humanized IgG4 ĮLQWHJULQ 7-15 IV 300 mg W0-W2-W8 300 mg Every 4 weeks
Vedolizumab Humanized IgG1 ĮLQWHJULQ 15-22 SC 300 mg W0-W2 300 mg Every 4 weeks
,JLPPXQRJOREXOLQ,9LQWUDYHQRXV6&VXEFXWDQHRXV71)WXPRUQHFURVLVIDFWRU:ZHHN
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7DEOH$YDLODELOLW\DQGGUXJODEHOOLQJRIELRORJLFVDJHQWIRULQÀDPPDWRU\ERZHOGLVHDVH,%'10
Agent 3ULPDU\7DUJHW Route 6SHFL¿F/DEHOLQJ
Crohn’s Disease Ulcerative Colitis
%ORFNDGHSURLQÀDPPDWRU\F\WRNLQHV
,QÀL[LPDE TNF IV FDA and EMA approved FDA and EMA approved
Adalimumab TNF SC FDA and EMA approved FDA and EMA approved
Certolizumab pegol TNF SC FDA approved -
Golimumab TNF SC - FDA and EMA approved
CT-P13 TNF IV EMA approved EMA approved
TNF-Kinoid TNF IV Phase II (-) -
HMPL-004 71)DQG,/ Oral Ongoing Phase III Ongoing Phase III
Ustekimumab IL-12/IL-23 (p40 subunit) IV/SC Ongoing Phase III -
AMG139 IL-23/IL-23R interaction IV Ongoing Phase II -
BI 655066 IL-23 (p19 subunit) SC Ongoing Phase II -
PF-04236921 IL-6 SC Ongoing Phase I/II -
Tralokinumab IL-13 SC - Phase II (-)
Anrunkinzumab IL-13 receptor IV - Phase II (-)
QAX576 IL-13 IV Ongoing Phase II -
Bertilizumab Eotaxin-1 IV - Ongoing Phase II
9LGRÀXLGLPXV IL-17 release Oral Phase II (+) Phase II (+)
ATR-107 IL-21 receptor IV/SC Ongoing Phase I -
NNC0114-0006 IL-21 IV Ongoing Phase II -
Blockade of the downstream signalling pathway mediated by cytokine
Tofacitinib JAK 1,2,3 Oral Ongoing Phase III Ongoing Phase III
3H¿FLWLQLE JAK 1 Oral - Ongoing Phase II
GLPG0634 JAK 1 Oral Ongoing Phase II -
GED0301 (mongersen) Smad7 antisense oligonucleotide Oral Phase I (+) -
BMS-936557 IP-10 antagonists IV Ongoing Phase II Phase II (±)
Masitinib (AB1010) Tyrosine kinase receptor IV Ongoing Phase II -
Anti adhesion molecules
Natalizumab Į,QWHJULQ IV FDA approved -
Vedolizumab Į,QWHJULQ IV Phase III (±) Phase III (+)
Ertolizumab ,QWHJULQ IV/SC - Phase II (+)
PF-00547659 MadCAM-1 IV/SC Ongoing Phase II Ongoing Phase II
AJM300 Į,QWHJULQ Oral - Phase II (+)
Alicaforsen ICAM-1 Oral/
intra-rectal
Phase II (-) Phase II (+)
Vatelizumab Į,QWHJULQ SC - Ongoing Phase II
Firategrast Į,QWHJULQ Oral Ongoing Phase II -
GLPG0974 FFA-2 Oral - Ongoing Phase II
TRK-170 ,QWHJULQ Oral Ongoing Phase II -
$QWLLQÀDPPDWRU\F\WRNLQH
Low dose IL-2 IL-2 SC Ongoing Phase II Ongoing Phase II
Blockade of T-cell stimulation and induction of apoptosis
SB-012 GATA-3 Intrarectal - Ongoing Phase I/II
VB-201 TLR-2 dependent innate cell 
activation
Oral - Ongoing Phase II
GSK1399686 Ribosomal 50S subunit Oral - Ongoing Phase II
Laquinimod ? Oral Phase II (+) -
DIMS0150 TLR9 Intrarectal - Ongoing Phase III
Other mechanism
Fingolimod Sphingosine 1-phosphate 1 
receptor
Oral Ongoing phase I -
RPC1063 Sphingosine 1-phosphate 1 
receptor
Oral - Ongoing Phase II
GSK 1399686 Ribosomal 50S subunit Oral - Ongoing Phase II
(0$(XURSHDQ0HGLFLQHV$JHQF\)'$)RRGDQGGUXJDGPLQLVWUDWLRQ))$IUHHIDWW\DFLGUHFHSWRU,&$0,QWHU&HOOXODU$GKHVLRQ0ROHFXOH,J
LPPXQRJOREXOLQ,/LQWHUOHXNLQ,3LQWHUIHURQȖinducible SURWHLQ,9LQWUDYHQRXV-$.-DQXVNLQDVH0DG&$0PXFRVDODGGUHVVLQFHOODGKHVLRQ
PROHFXOH1.*'QDWXUDONLOOHUJURXSPHPEHU'6&VXEFXWDQHRXV71)WXPRUQHFURVLVIDFWRU7*)WUDQVIRUPLQJJURZWKIDFWRU7/57ROOOLNHUHFHSWRU
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7DEOH&RPSDUDWLYHHI¿FDF\RIELRORJLFVDJHQWDVLQGXFWLRQDQGPDLQWHQDQFHWKHUDS\IRUDQWL71)WKHUDS\QDwYHVXESRSXODWLRQ12
,QGXFWLRQ
7KHUDS\ ,QÀL[LPDE *ROLQXPDE $GDOLPXPDE
Clinical response
Vedolizumab OR = 0.78 (95% CrI: 0.39-1.64) OR = 1.25 (95% CrI: 0.62-2.56) OR = 1.69 (95% CrI: 0.86-3.43)
,QÀL[LPDE - OR = 1.61 (95% CrI: 0.94-2.74) OR = 2.19 (95% CrI: 1.35-3.55)
Golinumab - - OR = 1.36 (95% CrI, 0.85-2.13)
Clinical Remission
Vedolizumab OR = 0.88 (95% CrI: 0.30-2.86) OR = 1.26 (95% CrI: 0.4-4.43) OR = 2.48 (95% CrI: 0.86-8.11)
,QÀL[LPDE - OR = 1.44 (95% CrI: 0.65-3.14) OR = 2.81 (95% CrI: 1.49-5.49)
Golinumab - - OR = 1.95 (95% CrI: 0.96-4.10)
Mucosal Healing
Vedolizumab OR = 0.86 (95% CrI: 0.38-1.91) OR = 1.54 (95% CrI: 0.76-3.09) OR = 1.92 (95% CrI: 0.97-3.76)
,QÀL[LPDE - OR = 1.79 (95% CrI: 0.96-3.42) OR = 2.23 (95% CrI: 1.21-4.14)
Golinumab - - OR = 1.24 (95% CrI: 0.79-1.98)
Durable Clinical response
Vedolizumab OR = 3.18 (95% CrI: 1.14-9.20) OR = 2.33 (95% CrI: 1.04-5.41) OR = 3.96 (95% CrI: 1.67-9.84)
,QÀL[LPDE - OR = 0.73 (95% CrI: 0.31-1.77) OR = 1.24 (95% CrI: 0.51-3.15)
Golinumab - - OR = 1.69 (95% CrI: 0.85-3.70)
Clinical Remission
Vedolizumab OR = 2.93 (95% CrI: 1.03-8.28) OR = 2.03 (95% CrI: 0.84-5.05) OR = 1.81 (95% CrI: 0.74-4.90)
,QÀL[LPDE - OR = 0.69 (95% CrI: 0.29-1.77) OR = 0.63 (95% CrI: 0.24-1.63)
Golinumab - - OR = 0.90 (95% CrI: 0.43-1.98)
Mucosal Healing
Vedolizumab OR = 2.43 (95% CrI: 0.87-6.66) - OR = 3.21 (95% CrI: 1.33-7.35)
,QÀL[LPDE - - OR = 1.31 (95% CrI: 0.57-3.12)
Golinumab - - -
&U,FUHGLEOHLQWHUYDO25RGGVUDWLR1RWH7UHDWPHQWHIIHFWHVWLPDWHVFRPHIURP%D\HVLDQPL[HGWUHDWPHQWFRPSDULVVRQ25V!
IDYRXUWKHWUHDWPHQWLQWKHFROXPQ6KDGLQJFHOOVKRZQWKHVLJQL¿FDQWO\GLIIHUHQFHUHVXOWV
)LJXUH)RUHVWSORWRIWKHRGGVUDWLRIRUELRORJLFVDJHQWYVSODFHERIRUXOFHUDWLYHFROLWLV$,QGXFWLRQVWXGLHV%0DLQWHQDQFH
VWXGLHV&U,FUHGLEOHLQWHUYDO11
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7DEOH5HVXOWRIQHWZRUNPHWDDQDO\VLVRIELRORJLFVDJHQWLQWUHDWPHQWRI&URKQ¶VGLVHDVH13
Remission 
,QGXFWLRQ &RPSDUDWRU25&U,
aSUREDELOLW\LQWHUYHQWLRQVXSHULRUWRFRPSDUDWRUJUHDWHURGGVRIUHPLVVLRQ
Intervention Placebo Aza+6-mercap Mtx Certo ,QÀL[ Adal
Aza+ 6-Mercap 1.2 (0.76–2.1), 81% - - - - -
Mtx 1.5 (0.72–3.2), 88% 1.3 (0.49–2.9), 71% - - - -
Certo 1.4 (0.95–2.0), 96% 1.1 (0.58–2.0), 63% 0.89 (0.40–2.1), 
38%
- - -
,QÀL[ 2.8 (1.4–7.2), >99% 2.3 (1.3–5.0), >99% 1.8 (0.69–6.4), 
89%
2.1 (0.98–5.5), 
97%
- -
Adal 2.9 (1.6–5.5), >99% 2.4 (1.0–4.9), 98% 1.9 (0.76–4.8), 
92%
2.1 (1.0–4.6), 
98%
1.0 (0.32–2.4), 
53%
-
Vedolizumab 2.0 (1.2–3.3), >99% 1.6 (0.78–3.2), 91% 1.3 (0.53–3.2), 
71%
1.4 (0.77–2.7), 
89%
0.70 (0.25–1.5), 
20%
0.67 (0.33–1.5), 
15%
aAn OR greater than 1 favors the intervention (row) over the comparator (column), indicating a greater odds of induction of remission.
Aza+ 6-Mercap 1.7 (1.3–2.6), >99% - - - - -
Mtx 2.4 (1.1–4.8), 98% 1.4 (0.58–2.8), 78% - - - -
Certo 2.0 (1.4–3.0), >99% 1.2 (0.65–1.9), 72% 0.85 (0.39–2.1), 
34%
- -
,QÀL[ 2.8 (1.8–4.5), >99% 1.6 (1.0–2.5), 98% 1.2 (0.51–2.8), 
65%
1.4 (0.77–2.6), 
87%
- -
Adal 5.1 (3.3–8.1), >99% 2.9 (1.6–5.1), >99% 2.1 (0.96–5.0), 
97%
2.5 (1.4–4.6), 
>99%
1.8 (0.94–3.4), 
96%
-
Vedolizumab 2.2 (1.3–3.7), >99% 1.3 (0.65–2.3), 76% 0.91 (0.39–2.3), 
42%
1.1 (0.57–2.1), 
59%
0.77 (0.39–1.5), 
22%
0.42 (0.22–0.85), 
1%
a$Q25JUHDWHUWKDQIDYRUVWKHLQWHUYHQWLRQURZRYHUWKHFRPSDUDWRUFROXPQLQGLFDWLQJDJUHDWHURGGVRIPDLQWDLQLQJUHPLVVLRQ$GDODGDOLPXPDE$]D
D]DWKLRSULQH&HUWR&HUWROL]XPDE,QÀL[LQÀL[LPDE0HUFDSPHUFDSWRSXULQH0W[PHWKRWUH[DWH
remission in CD were adalimumab and combination 
RILQÀL[LPDEZLWKD]DWKLRSULQH7DEOH13
$'9(56(())(&72)%,2/2*,&$/7+(5$3<
Besides effective for treating of both CD and UC, 
some obstacle happened in using biologics agent. 
Limitations of anti-TNF treatment is realated to safety 
issues, relatively high cost, and loss of effectiveness.2,3 
Anti-TNF treatment known to increase the risk of 
LQIHFWLRQ WKHXVHRI LQÀL[LPDEZDV DVVRFLDWHGZLWK
a 1.4- to 1.6-fold increase in serious infections. TNF 
is important for granuloma formation, and the use of 
anti-TNF agents has been reportedly associated with a 
¿YHIROGLQFUHDVHGULVNRIWXEHUFXORVLV$QWL71)WKHUDS\
also associated with hepatitis B reactivation. The use of 
anti-TNF drugs also has been associated with a small 
risk of malignancy, which dose-dependent, from non-
melanome skin cancer and non-Hodgkin lymphoma. 
The rik will further increase in patient who also receive 
immunosuppressants therapy.9,10 Physicians should be 
aware that anti-TNF antibodies may cause psoriasiform 
skin lesions in some patients with IBD. The anti-IL-12/
IL-23 antibody, ustekinumab, is effective for the 
WUHDWPHQWRIWKLVSDUDGR[LFDOLQÀDPPDWLRQ10
Before starting anti-TNF treatment, a thorough 
evaluation is mandatory. Anti-TNF agent should be 
used with caution for patient with systemic lupus 
erythematosus and should not be used in patient 
with malignancy or premalignant disorder. The most 
common infections was bacterial and fungal infections 
including aspergillosis, cryptococcosis, candidosis, 
histoplasmosis, listeriosis, pneumocytosis and 
reactivated tuberculosis.14
%,26,0,/$56 ,1 ,1)/$00$725< %2:(/
DISEASE (IBD)
Biologics medicines comprise proteins or other 
substances derived from a biological source. A 
biosimilar product is a biological product that is 
highly similar to a reference product. Biosimilar 
agent is not identical to the reference product, but the 
active ingredients are essentially the same as those of 
the reference product with no clinically meaningful 
GLIIHUHQFHVLQWHUPVRIVDIHW\RUHI¿FDF\7KHVHGUXJV
are intended to be designed as a less expensive version 
of the reference product, biosimilars can reduce up 
to 72% budget compared to the original biological 
product in some countries. With the introduction of 
biosimilars, it is eagerly expected that patient access to 
biologics therapy will expand and the economic burden 
for health-care sys tems will decrease. Biosimilars 
represent a new generation of drugs for the treatment of 
,%'ZLWKFRPSDUDEOHVDPHHI¿FDF\DQGVDIHW\SUR¿OH
as original biologics agent, especially in countries with 
low economy capacity. Other biosimilar drugs that 
KDYHEHHQGHYHORSHGFDQEHVHHQRQ¿JXUHEHORZ9-11
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CONCLUSION
Immunological imbalance of the intestinal mucosa 
DQG LQÀDPPDWRU\ FRQGLWLRQ LQ ,%'SDWLHQWV DUH WKH
main target of these new biologics agent. With the more 
understanding in the pathological proccess in IBD 
recently the biological therapy is developing. These 
agents are used in IBD patients, who are refractory to 
standard medications. Several parameters about the 
drugs should be taken into account to help physicians 
through the decision-making process, including the 
FRPSDUDWLYHHIIHFWLYHQHVVDQGORQJWHUPVDIHW\SUR¿OH
availability and labelling in the prescriber’s country, 
international guidelines, and cost as well as patient 
preferences associated with the route of administration. 
As an alternative, biosimilars are already available 
in the market and increased competition will lead 
to decreased costs and increased availability and 
accessibility of biological therapy. Although, it still 
need more research about efectivity, safety and 
applicability for this therapy. It is essential to provide 
patients with adequate, comprehensible and easily 
accessible treatment.
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